RecruitingNCT06892704

Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.

Olfactory Cleft Obstruction and Electrophysiological Olfactory Bulb Generated Beta Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.


Sponsor

Northwestern University

Enrollment

30 participants

Start Date

May 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are: 1. Does obstruction of the olfactory cleft predict return of the sense of smell? 2. Do electrophysiological signals generated by breathing and sniffing behavior predict return of the sense of smell? Participants starting dupilumab will undergo assessment for their degree of olfactory cleft obstruction, and an electrophysiologic assessment of their olfactory cleft and be followed over 6 months of treatment with dupilumab.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria4

  • Well documented history of CRSwNP
  • BSIT age/sex classified as "abnormal" score
  • Self-reported stable olfactory deficit of moderate to severe quality \> 3 months
  • Prior endoscopic sinus surgery \>3 months, \<10 years prior

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDupilumab - Standard Dose

24 weeks of dupilumab 300mg q2 weeks


Locations(1)

Northwestern University Feinberg School of Medicine

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06892704


Related Trials